journal article·2025-06-17

Cascade Magnetic Hyperthermia Therapy for Biofilm Eradication and Bone Regeneration via Dual Osteoimmuno-regulation

Lingtian Wang, Hao Fu, Jinhui Zhao, Zihao Liu, Saisai Chen, Chang-Qing Zhang, Ping Hu, Jiaxing Wang, Jianlin Shi, Weitao Jia

ACS Nano· Volume 19· Issue 23
Publisher page

Abstract

Infected bone defects (IBDs) treatment presents a great challenge in current orthopedics due to the complex nature of these defects, and the diversified demands involving infection control and subsequent bone regeneration. Current-available treatments often fail to address these multifaceted needs effectively. Herein, we propose a cascade magnetic hyperthermia therapy (cMHT) strategy using MNP-PEI-siCkip-1 (MPSC), a magnetogenetic nanoplatform constructed by coating siRNA for casein kinase-2 interacting protein-1 (siCkip-1) and polyethylenimine-carboxylic acid (PEI-COOH) on ZnCoFe 2 O 4 @ZnMnFe 2 O 4 nanoparticles. These MPSCs were then embedded in gelatin methacryloyl (GelMA) to form a nanocatalytic nanoparticle-hydrogel composite (MSG), which exhibited a strong magnetothermal effect. During the disinfection period, the MSG hydrogel generates MHT (∼50 °C) under alternative magnetic field (AMF) to destroy dense biofilm, and catalytically produce hydroxyl radicals (•OH) in biofilm microenvironment (BME) for anti-infection. Increased •OH production also promotes the proinflammation regulation of innate immunity for bacteria eradication. After the infection elimination, AMF was tuned to induce mild MHT (∼41 °C, mMHT) to promote osteogenesis and suppress excessive inflammation. Gradual MSG hydrogels degradation releases MPSCs, delivering siCkip-1 possessing osteogenic and anti-inflammatory activities to osteoblasts and macrophages. This cascade magnetic hyperthermia therapy (cMHT) strategy offers a compelling solution to the multifaceted challenges of IBD treatment, addressing critical aspects such as infection control and bone regeneration. The innovative approach underscores a promising potential of cMHT as transformative therapeutic option for IBDs, which may lead to improved treatment outcomes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Alkaline Phosphatase Research Studies · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics

Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Department of Orthopedics

The First Affiliated Hospital of Wenzhou Medical University

State Key Laboratory of High Performance Ceramics and Superfine Microstructure

Shanghai Institute of Ceramics, Chinese Academy of Sciences

Department of Orthopedics, Shanghai Tenth People’s Hospital, School of Medicine

Tongji University

Funding

National Key Research and Development Program of China · School of Medicine, Shanghai Jiao Tong University · National Natural Science Foundation of China · Program of Shanghai Academic Research Leader · Jiangsu Research Institute of Advanced Inorganic Materials Industrialization Fund Project of the Biomedical Materials Innovation Center

References (44)

Show source-provided references
1. 10.1016/j.copbio.2011.02.00510.1016/j.copbio.2011.02.005 ↗
2. 10.1038/s41413-019-0061-z10.1038/s41413-019-0061-z ↗
3. 10.1038/s41579-018-0019-y10.1038/s41579-018-0019-y ↗
4. 10.4049/jimmunol.100279410.4049/jimmunol.1002794 ↗
5. 10.1038/s41564-020-0756-310.1038/s41564-020-0756-3 ↗
6. 10.1128/mBio.01918-1810.1128/mBio.01918-18 ↗
7. 10.1073/pnas.172194911510.1073/pnas.1721949115 ↗
8. 10.1016/j.chom.2019.02.00710.1016/j.chom.2019.02.007 ↗
9. 10.1002/adfm.20221473410.1002/adfm.202214734 ↗
10. 10.1016/j.bioactmat.2022.12.01310.1016/j.bioactmat.2022.12.013 ↗
11. 10.1002/advs.20220453510.1002/advs.202204535 ↗
12. 10.1038/nrrheum.2012.110.1038/nrrheum.2012.1 ↗
13. 10.1038/nrd366910.1038/nrd3669 ↗
14. 10.1002/advs.20230419010.1002/advs.202304190 ↗
15. 10.1002/adfm.20241092710.1002/adfm.202410927 ↗
16. 10.1016/j.cej.2023.14679710.1016/j.cej.2023.146797 ↗
17. 10.1038/s41579-022-00686-010.1038/s41579-022-00686-0 ↗
18. 10.4049/jimmunol.190095310.4049/jimmunol.1900953 ↗
19. 10.1039/D2TB01200F10.1039/D2TB01200F ↗
20. 10.1016/j.nantod.2022.10160210.1016/j.nantod.2022.101602 ↗
21. 10.1016/j.cej.2022.13721410.1016/j.cej.2022.137214 ↗
22. 10.1016/j.biomaterials.2019.11937410.1016/j.biomaterials.2019.119374 ↗
23. 10.1016/j.biomaterials.2020.12007910.1016/j.biomaterials.2020.120079 ↗
24. 10.1093/nsr/nwac16910.1093/nsr/nwac169 ↗
25. 10.1021/acsnano.0c0525510.1021/acsnano.0c05255 ↗
26. 10.1002/adma.20230343210.1002/adma.202303432 ↗
27. 10.1038/s41420-021-00491-310.1038/s41420-021-00491-3 ↗
28. 10.1155/2012/84913610.1155/2012/849136 ↗
29. 10.1016/j.nantod.2022.10140110.1016/j.nantod.2022.101401 ↗
30. 10.1002/smll.20220269110.1002/smll.202202691 ↗
31. 10.1016/j.cellsig.2017.02.01510.1016/j.cellsig.2017.02.015 ↗
32. 10.1021/acsami.7b1207910.1021/acsami.7b12079 ↗
33. 10.1021/jacs.3c0204910.1021/jacs.3c02049 ↗
34. 10.1021/acs.biomac.3c0027910.1021/acs.biomac.3c00279 ↗
35. 10.1016/j.jsamd.2020.01.00710.1016/j.jsamd.2020.01.007 ↗
36. 10.1016/j.tibtech.2013.06.00510.1016/j.tibtech.2013.06.005 ↗
37. 10.1016/j.tibtech.2013.06.00510.1016/j.tibtech.2013.06.005 ↗
38. 10.1038/s41419-020-2497-x10.1038/s41419-020-2497-x ↗
39. 10.1126/scitranslmed.300118010.1126/scitranslmed.3001180 ↗
40. 10.1016/j.biomaterials.2016.02.00410.1016/j.biomaterials.2016.02.004 ↗
41. 10.18632/aging.20384810.18632/aging.203848 ↗
42. 10.1038/cr.2014.5310.1038/cr.2014.53 ↗
43. 10.1016/j.imlet.2013.04.00110.1016/j.imlet.2013.04.001 ↗
44. 10.2353/ajpath.2006.05115510.2353/ajpath.2006.051155 ↗